Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|General Practice · NATRONA HEIGHTS, PA · NPI 1871568162
Verified facts
CMS Open Payments records show Shashikala Sarma received $26.78 in general payments during 2025 across 1 reported records.
Exact Sciences Corporation accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.78 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $26.78 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $26.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 593 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 537 | 159 |
| Pravastatin Sodium | Pravastatin Sodium | 451 | 130 |
| Lisinopril | Lisinopril | 447 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 430 | 131 |
| Losartan Potassium | Losartan Potassium | 368 | 110 |
| Metformin Hcl Er | Metformin Hcl | 319 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 87 |
| Omeprazole | Omeprazole | 285 | 91 |
| Famotidine | Famotidine | 223 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 222 | 47 |
| Gabapentin | Gabapentin | 220 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 76 |
| Eliquis | Apixaban | 173 | 41 |
| Furosemide | Furosemide | 142 | 50 |
| Metformin Hcl | Metformin Hcl | 141 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 46 |
| Sertraline Hcl | Sertraline Hcl | 134 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 49 |
| Ezetimibe | Ezetimibe | 116 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 46 |
| Jardiance | Empagliflozin | 111 | 28 |
| Ozempic | Semaglutide | 102 | 26 |
| Meloxicam | Meloxicam | 92 | 41 |
| Trazodone Hcl | Trazodone Hcl | 91 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 28 |
| Mounjaro | Tirzepatide | 87 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 82 | 19 |
| Simvastatin | Simvastatin | 82 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 30 |
| Potassium Chloride | Potassium Chloride | 80 | 29 |
| Buspirone Hcl | Buspirone Hcl | 79 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 22 |
| Spironolactone | Spironolactone | 76 | 24 |
| Atenolol | Atenolol | 72 | 24 |
| Carvedilol | Carvedilol | 67 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 16 |
| Montelukast Sodium | Montelukast Sodium | 59 | 18 |
| Allopurinol | Allopurinol | 58 | 18 |
| Glimepiride | Glimepiride | 58 | 17 |
| Lovastatin | Lovastatin | 50 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 45 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 14 |
| Synthroid | Levothyroxine Sodium | 42 | 12 |
| Prednisone | Prednisone | 41 | 25 |
| Alendronate Sodium | Alendronate Sodium | 40 | 16 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Xarelto | Rivaroxaban | 38 | 13 |
| Azelastine Hcl | Azelastine Hcl | 37 | 12 |
| Tradjenta | Linagliptin | 36 | 13 |
| Ketoconazole | Ketoconazole | 34 | 14 |
| Valsartan | Valsartan | 32 | 11 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Repaglinide | Repaglinide | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 18 |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 16 |
| Cephalexin | Cephalexin | 16 | 14 |
| Colchicine | Colchicine | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $26.78 · 1 records | Exact Sciences Corporation | The Cologuard Plus Collection Kit | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error